What is Prevention of Mother-to-Child Transmission (option B+)?

Stopping the spread of HIV/AIDS from mothers to their children is a first step to curbing the epidemic. In Swaziland, since February 2013, Médecins Sans Frontières has rolled out an innovative approach called PMTCT B+.







HIV positive pregnant women

HIV positive breast-feeding women

With this approach, women start a life-long antiretroviral (ARV) treatment rapidly after being screened HIV positive, regardless of the status of their immune system.

From testing to treatment

Getting people tested is often a challenge. Expert patients, who are themselves HIV-positive, are important advocates for encouraging people to get tested and know their HIV status.





With the introduction of the PMTCT B+ approach, the risk of transmission of HIV from mother to child is further reduced.

Pregnant women screened HIV-positive start life-long antiretroviral treatment rapidly, regardless of their CD4 count*.

*CD4 count: a measurement of the strength of a patient's immune system







New born babies take preventive treatment in syrup form for six weeks after birth. The baby will undergo another HIV test at six weeks to confirm he/she is HIV-negative.

Benefits of PMTCT B+ approach

Protect HIV-negative partners



Prevent transmission of the virus in future pregnancies



Allow HIV-positive mothers to live longer by reducing the risk of developing opportunistic infections





PMTCT B+ is a first step to envision an HIV-free Swaziland.